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Abstract
Cancer was initially thought to be just a disease of cells with deregulated gene ex‐
pression. It may be more accurate to consider cancer as a disease of the microenvir‐
onment. Despite the remarkable and fairly rapid progress over the past two decades
regarding the role of the microenvironment in cancer biology and treatment, our un‐
derstanding of its actual contribution to cancer resistance is still poor and fragment‐
ed. Nevertheless, the microenvironment is now considered to be of critical
importance during the initiation and progression of carcinogenesis since it is in‐
volved in shaping and remodeling stroma reactivity and in reprogramming pheno‐
typic and functional plasticity. Therefore, the tumor microenvironment represents an
important hallmark of cancer, and the challenge now is to better understand how the
tumor microenvironment participates in the emergence of immune-resistant tumor
cell variants, which appears to be the greatest impediment to successful immuno‐
therapy. In this context, autophagy has recently emerged as a new player in regulat‐
ing the antitumor immune response under hostile tumor microenvironment. In this
review, we will summarize recent data describing how autophagy activation under
hypoxic stress impairs the antitumor immune response. In addition, we will discuss
how tumor manages to hide from the immune attack and either mounts a “counter‐
attack” or develops resistance to immune cells. In particular, we will focus on the ef‐
fect of hypoxia-induced autophagy in allowing tumor cells to outmaneuver an
effective immune response and escape from immunosurveillance. It is our belief that
autophagy may represent a conceptual realm for new immunotherapeutic strategies
aiming to block immune escape and therefore providing rational approach to future
tumor immunotherapy design.
Keywords: Autophagy, hypoxia, tumor immunity, immunotherapy, immune surveil‐
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1. Introduction
In addition to malignant cells, tumors contain cells of the immune system, the tumor vascu‐
lature, and lymphatics as well as fibroblasts, pericytes, and adipocytes. Cells of the immune
system can identify and destroy tumor cells in a process termed cancer immunosurveillance.
Several types of immune cells are involved in tumor immune surveillance. Briefly, key cells of
the adaptive immune system identifying cancer cells are cytotoxic T lymphocytes (CTL), which
are able to recognize tumor antigens via the T-cell receptor (TCR) [1]. Some of these antigens
are expressed exclusively by tumors and thus are called tumor-specific antigens [1]. Natural
killer (NK) cells of the innate immune system also play an important role in tumor immune
surveillance [1] by mechanisms called “missing-self” and “induced-self” recognitions [2]. In
addition to CTL and NK cells, macrophages and neutrophil granulocytes are also involved in
antitumor immunity [3]. Macrophages are antigen presenting cells (APCs) that display tumor
antigens and stimulate other immune cells such as CTL, NK cells, and other APCs [4]. While
the molecular mechanism by which CTL and NK cells recognize their target tumor cells is
fundamentally different, both immune cells kill their target following the establishment of
immunological synapse (IS) [5]. The formation of IS requires cell polarization and extensive
remodeling of the actin cytoskeleton at various stages [6]. It is now well established that CTL
and NK cells recognize and kill target cells by two major pathways: either through the release
of cytotoxic granules containing perforin and granzymes to the cytosol of target cells [7] or
through tumor necrosis factor (TNF) super family-dependent killing [8].
Although various  immune effector  cells  are  recruited to  the  tumor site,  their  antitumor
functions  are  largely  downregulated  in  response  to  several  microenvironmental  factors.
Indeed,  hypoxic  stress  in the tumor microenvironment,  which is  the result  of  an inade‐
quate  oxygen  supply  to  the  cells  and  tissues,  is  a  characteristic  feature  of  locally  ad‐
vanced  solid  tumors  and  is  considered  as  the  major  mechanism  responsible  for  tumor
resistance to therapies [9].
Experimental and clinical evidence indicates that the majority of mechanisms suppressing the
antitumor immune functions are directly evolved in the hypoxic tumor microenvironment
(reviewed in [10]). Thus, NK cells and natural killer T (NKT) cells infiltrate the tumor micro‐
environment but are not found in contact with tumor cells [11]. It has been reported that in
colorectal, gastric, lung, renal, and liver cancer NK cells appear to predict a good prognosis
[12]. However, although they are present in the tumor microenvironment, NK cells may not
be able to exert their tumor-killing function. A number of studies reported that NK cells in the
tumor stroma have an anergic phenotype that is induced by malignant cell-derived trans‐
forming growth factor beta (TGF-β) [13]. Furthermore, immune cells in the tumor microen‐
vironment not only fail to exercise antitumor effector functions but also co-opted to promote
tumor growth [14]. In addition, it has become clear that the immune system not only protects
the host against tumor development but also sculpts the immunogenic phenotype of a
developing tumor and can favor the emergence of resistant tumor cell variants [15]. Thus, it
has become obvious that the evasion of immunosurveillance by tumor cells is under the control
of the tumor microenvironment complexity and plasticity. Reactivating the immune system
for therapeutic benefit in cancer has therefore long been a goal in cancer immunotherapy.
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After decades of disappointment, cancer immunotherapy has recently emerged as a promising
treatment of several cancers for which conventional therapies have failed [16]. Notably, the
success of the recent proof-of-concept clinical trials of anticytotoxic T-lymphocyte-associated
protein 4 (anti-CTLA4) and anti-programmed cell death 1 (anti-PD-1) based on reactivating
the adaptive immune response claims that the tide has finally changed. This success is mainly
attributed to an increase in our understanding of the mechanisms regulating tumor cell
cytotoxicity mediated by immune cells. For several years, our group has been able to partici‐
pate in this understanding by studying the mechanism responsible for the tumor escape from
the immune surveillance [17, 18], which still represents the major obstacle for defining efficient
cancer immunotherapeutic approaches. Therefore, it remains important to better understand
how tumor cells manage to outmaneuver the immune system and evade effective immuno‐
surveillance.
2. Hypoxic stress in the tumor microenvironment
Hypoxia in the tumor microenvironment commonly refers to a condition in tumors where the
pressure of oxygen is lower than 5–10 mm Hg. The adaption of tumors to hypoxic stress is
regulated by hypoxia inducible factor family of transcription factors (HIFs). It has been
demonstrated in a large number of human cancer cases and/or incidents that HIFs were
overexpressed and such overexpression is associated with poor response to treatment [19].
Moreover, evidence showed a clear positive correlation between enhanced hypoxic expression
of HIFs and mortality [20].
2.1. Hypoxia-inducible factors
Three isoforms of HIF have been identified: HIF-1, HIF-2, and HIF-3. HIF-1 and HIF-2 (also
known as EPAS1) have the same structure and are well characterized. However, HIF-3 acts as
a negative regulator of HIF-1 and HIF-2 [21]. HIF-1 is ubiquitously expressed in all mammalian
cells, whereas HIF-2 and HIF-3 are selectively expressed in certain tissues such as vascular
endothelial cells, type II pneumocytes, renal interstitial cells, liver parenchymal cells, and cells
of the myeloid lineage [22].
HIF-1 is a heterodimer composed of a constitutively expressed subunit and an O2-regulated
subunit, HIF-1β, and HIF-1α, respectively [23]. In the presence of oxygen, HIF-1α is hydroxy‐
lated on a proline residue by prolyl hydroxylase domain protein 2 (PHD2), which leads to an
interaction with the von Hippel–Lindau (VHL) protein [24]. This allows the recruitment of an
E3 ubiquitin ligase that catalyzes the polyubiquitination of HIF-1α and its subsequent
degradation by ubiquitin proteasome system (UPS) [24]. Under hypoxia, the hydroxylation of
HIF-1α is inhibited, and HIF-1α is accumulated and translocated to the nucleus where it forms
a dimer with HIF-1β and activates the transcription of several genes involved in many
biological processes [24]. Similar to HIF-1α, HIF-2α is also regulated by oxygen-dependent
hydroxylation. While the effect of hypoxia on suppressing the activity of immune cells is
relatively well defined, the mechanisms by which hypoxia educates tumor cells to escape an
effective immune cell mediated killing are still largely elusive.
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2.2. Hypoxia-induced autophagy
Although autophagy can be activated in response to different stimuli, including nutrient
starvation and/or growth factors withdrawal, hypoxic stress is the major activator of autoph‐
agy in the tumor microenvironment [25]. Indeed, emerging recent data have showed that
hypoxia-induced autophagy is an important regulator of the innate and adaptive tumor
immunity mediated by NK cells and CTL, respectively. In particular, hypoxia has been
described to play a central role in activating multiple overlapping adaptive mechanisms
involving autophagy and leading to the emergence of resistant tumor cells able to outmaneu‐
ver an effective immune response and escape from immune cell killing. In this context, we
have recently showed that the activation of autophagy in tumor cells under hypoxia dramat‐
ically decreases tumor cell susceptibility to NK- and CTL-mediated lysis [17, 26]. Therefore,
autophagy activation is considered to be an important adaptive and resistance mechanism
operating in tumor cells to escape the immune system. In accordance with such a role of
autophagy, Lotze et al. showed that NK cells along with human peripheral blood lymphocytes
are primary mediators in inducing autophagy in several human tumors promoting cancer cell
survival [27]. Other studies showed that autophagy also plays an important role in regulating
CTL-mediated antitumor immune response. While the molecular mechanisms by which
autophagy impairs tumor susceptibility to NK and CTL are different, experimental evidence
claims that blocking autophagy may improve tumor immunity.
Autophagy is a lysosomal degradation pathway that allows the cell to self-digest its own
components, getting rid of excessive or damaged organelles and misfolded proteins in the cell.
Such degradation process provides nutrients to maintain crucial cellular functions under
nutrient deprivation, thus allowing the survival of cancer cells [28]. It has been reported that
the activation of autophagy under hypoxic stress in tumor cells occurs either by HIF-1-
dependent or -independent manner. In this section, we will briefly describe the different
mechanisms involved in the activation of autophagy.
2.2.1. HIF-1-dependent activation of autophagy
Under hypoxia, HIF-1α is stabilized, and its heterodimerization with HIF-1β allows the
binding of the transcription factor to hypoxia response elements (HREs) in target genes [9].
HRE is a cis-acting hypoxia response element (5′-TACGTGCT-3′), which can be located in
either the 5′ or the 3′ regions of the genes [29] to confer oxygen regulation of genes expression
[29–32]. The activation of HIF-1α-dependent autophagy occurs via the induction of the Bcl-2
(B-cell lymphoma 2)/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), which
contains two HRE sites in its promoter region: HRE1 and HRE2. It has been demonstrated that
HIF-1 directly binds to HRE2 site in order to induce the expression of BNIP3 [33], thus leading
to the disruption of the autophagy inhibitory complex BECN1/Bcl-2 and the subsequent release
of Beclin1 (BECN1) to promote the activation of autophagy.
2.2.2. HIF-1-independent activation of autophagy
Despite the role of HIF-1 in the regulation of autophagy under hypoxic conditions, it remains
important to note the existence of other pathways that may regulate autophagy under hypoxia
independently of HIF-1. Recently, two pathways that influence gene expression and tumor
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cell behavior have been described to be O2 sensitive [34]. One of them occurs through the
regulation of the mammalian target of rapamycin (mTOR) and its downstream effectors that
orchestrate several biological processes, including autophagy. Indeed, mTOR signaling
consists of two major pathways mediated by the specific mTOR complexes mTORC1 and
mTORC2. It has been reported that mTORC1 negatively controls autophagy by the inhibition
of protein kinase ATG1 involved in the formation of autophagosomes [35]. Hypoxia inhibits
mTORC1 through multiple pathways; one of them is mediated through hypoxic activation of
the tuberous sclerosis protein (TSC) complex, which is a heterodimeric complex formed by
TSC1 and TSC2 [36]. The 5′ AMP-activated protein kinase (AMPK) is a heterotrimeric complex
encoded by several genes and is the primary energy sensor in cells. Upon its activation through
the increase in the AMP/ATP ratio, AMPK phosphorylates many downstream targets,
including TSC2. TSC2 phosphorylation on serine residues 1270 and 1388 enhances the activity
of the TSC1/TSC2 complex and thereby blocks the Ras homolog enriched in brain (RHEB)-
dependent activation of mTOR [37]. Another pathway that activates autophagy in an HIF-1-
independent manner is through the activation of the unfolded protein response (UPR), a
program of transcriptional and translational changes that occur as a consequence of endo‐
plasmic reticulum (ER) stress [38]. The UPR is mediated by three ER stress sensors: PKR-like
ER kinase (PERK), ER to nucleus signaling 1 (ERN1), and activating transcription factor (ATF)
6 [38]. In some conditions, autophagy appears to be mediated by PERK, whereas in others, it
occurs downstream of IRE1. For example, by inducing PERK-dependent phosphorylation of
the eukaryotic translation initiation factor 2 alpha (elF2α), hypoxia activates autophagy by the
transcriptional induction of LC3 through the expression of ATF4 [39].
2.2.3. Autophagy activation under nutrient starvation
Under starvation condition, autophagy is activated by several mechanisms. One of the well
described mechanisms is the regulation of autophagy by Reactive Oxygen Species (ROS) which
mainly comprise superoxide (O2), hydrogen peroxide (H2O2) and hydroxyl radical (OH).
Several studies have demonstrated that ROS-dependent activation of AMPK leads to the
inhibition of mTOR pathway under starvation conditions, thereby activating autophagy [40].
Furthermore, recent studies showed that the upregulation of NS5ATP9 previously identified
as p15PAF [proliferating cell nuclear antigen (PCNA)-associated factor] in starved HepG2 cells
plays a functional role in starvation-induced autophagy and contributes to tumor cell growth.
NS5ATP9 promotes autophagy by Beclin1-dependent manner under starvation condition.
Indeed NS5ATP9 upregulates Beclin-1 expression at the transcriptional level, thereby inducing
autophagy [41]. Another mechanism of autophagy activation under starvation conditions is
MK2/MK3-dependent Beclin1 phosphorylation. MK2/MK3 are two related stress-responsive
kinases members of p38 mitogen-activated protein kinase (MAPK) signaling pathway. Yobgjie
Wei et al. showed that MK2/MK3 phosphorylate Beclin1 at serine 90, and this phosphorylation
is essential for autophagy induction in response to nutrient starvation [42].
It has been reported in several studies that some microRNAs (miRNAs) are able to regulate
starvation-induced autophagy. Mature miRNAs are a class of noncoding RNAs that play key
roles in the regulation of gene expression by acting at the posttranscriptional level. miRNAs
are short, single-stranded RNA molecules ~22 nucleotides in length. They are partially
complementary to one or more messenger RNA (mRNA) molecules. By base pairing with
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sequences found mainly in the 3 untranslated region (3′ UTR) of specific mRNAs, miRNAs
downregulate gene expression by different manners, including translational repression. It has
been shown in several studies that some miRNAs are able to regulate starvation-induced
autophagy. Thus, miR376A and miR376B have been identified as regulators of autophagy
under starvation condition by blocking the expression of the two key autophagy proteins
ATG4C and BECN1. The inhibition of ATG4C and BECN1 by miR376A is achieved by directly
affecting specific MRE (miRNA response elements) sequences in 3′ UTR region. Another
autophagy-related miRNA miR181A was shown to regulate starvation-induced autophagy by
regulating ATG5 level containing a MRE on its 3′ UTR region. This regulation was observed
in MCF-7 breast cancer cells as well as in Huh-7 liver cancer and K562 chronic myelocytic
leukemia cell lines [43].
3. Hypoxia-induced autophagy as major regulator of the antitumor
immunity
Several lines of evidence highlight that hypoxia modulates both the activity of immune
effectors and the response of tumor cells to these effectors. In the following section, we will
summarize the effect of hypoxia-induced autophagy on the antitumor immune response
mediated by CTL and NK cells. Furthermore, we will discuss how autophagy activation
regulates tumor cell plasticity and leads to the emergence of resistant tumor cells able to
outmaneuver an effective immune response and escape from immune cell killing.
3.1. Hypoxia-induced autophagy impairs CTL-mediated tumor cell killing
Autophagy activation not only enables tumor cells to survive stress conditions during cancer
development but also provides them an intrinsic resistance mechanism against antitumor
immune response. The first evidence for such a role of autophagy was provided by Noman et
al. who demonstrated that hypoxic lung carcinoma cells can evade CTL-mediated lysis through
autophagy induction [26, 44] (Figure 1). Indeed, the inhibition of autophagy using small
interfering RNA (siRNA) directed against ATG5 or BECN1 restored tumor cells sensibility to
CTL-mediated lysis. This was correlated with a decrease in the hypoxia-dependent induction
of the phosphorylation of signal transducer and activator of transcription (STAT)-3. These
results allowed the prediction that blocking autophagy would suppress pSTAT3-dependent
survival mechanism making tumor cells more susceptible to CTL attack under hypoxia.
Considering the degradation role of autophagy, it is difficult, however, to perceive that
autophagy is involved in the stabilization of pSTAT3 under hypoxia. Focusing on the crosstalk
between the adaptor protein sequestosome1 (SQSTM1/p62), UPS and autophagy, this study
revealed that the induction of HIF-1α has two effects in tumor cells: (i) HIF-1α triggers the
phosphorylation of Src, which subsequently phosphorylates the tyrosine residue Y705 of
STAT3; (ii) HIF-1α activates autophagy by a mechanism involving the increased expression of
BNIP3/BNIP3L and the dissociation of the BECN1/Bcl-2 complex. Autophagy activation
results in the degradation of the p62 protein. Knowing that p62 is the receptor/adaptor protein
responsible for targeting pSTAT3 to the UPS, the autophagy-dependent degradation of p62
leads to the accumulation of pSTAT3. When autophagy is inhibited in tumor cells, the
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degradation of p62 is blocked and therefore p62 accumulates in tumor cells. This accumulation
accelerates the UPS-dependent degradation of pSTAT3 [26, 44]. The effect of the autophagy
inhibitor hydroxychloroquine (HCQ) was also evaluated in vivo in combination with a
tyrosinase-related protein-2 (TRP2) peptide-based vaccination strategy. Using a transplantable
murine melanoma B16-F10 cell line, evidence has been provided that autophagy is primarily
detected in hypoxic areas of the tumor. Inhibition of autophagy in B16-F10 engrafted tumors
results in a significant decrease in tumor growth by inducing apoptosis, as revealed by TUNEL
staining. These results strongly argue for a role of autophagy in mediating hypoxia tolerance
to the immune system. More interestingly, a significant decrease in tumor growth was
observed in vaccinated and HCQ-treated group of mice as compared to control and to
treatment alone. Although the subcutaneous tumor implantation models have their limits,
these results strongly argue that in vivo inhibition of autophagy improves the antitumor effect
of a TRP2-based vaccine.
Hypoxic stress
Cell death
HIF‐1
Src
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STAT3
pSTAT3 
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Beclin1
Bcl2
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Figure 1. Regulation of CTL-mediated tumor cell lysis by hypoxia-induced autophagy. Hypoxic stress leads to the ac‐
cumulation of HIF-1α. By a yet undefined mechanism, HIF-1α increases the level of phospho-Src, which subsequently
phosphorylates STAT3 at the Tyr705 residue. As HIF-target gene products, BNIP3 and BNIP3L are transcriptionally
upregulated and compete with the BECN1-BCL2 complex. This competition releases BECN1 from the complex and
then activates the autophagic machinery by recruiting several autophagic proteins, including ATG5. As an autophagic
substrate, p62/SQSTM1 is degraded in the autophagosomes following their fusion with lysosomes. In view of the fact
that p62/SQSTM1 is involved in targeting pSTAT3 to the UPS, its degradation leads to the accumulation of pSTAT3 in
cells. In autophagy-defective cells, p62/SQSTM1 is no longer degraded, and its accumulation accelerates the UPS-de‐
pendent degradation of pSTAT3.
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3.2. Hypoxia-induced autophagy impairs NK-mediated antitumor immune response
Recent evidence described how tumor cells can escape fully functional NK-mediated immune
surveillance by activating autophagy under hypoxia [17, 45] (Figure 2). Indeed, NK cells
recognize and kill their targets by several mechanisms, including the release of cytotoxic
granules containing perforin (PRF1) and serine protease granzyme B (GZMB). It has been
recently proposed that PRF1 and GZMB enter target cells by endocytosis and traffic to large
endosomes named “gigantosomes” [17, 45]. Subsequently, PRF1 is involved in the formation
of pores in the membrane of the “gigantosome,” leading to the gradual release of GZMB and
the initiation of apoptotic cell death. The formation of amphisomes following the fusion
between autophagic vacuoles and early endosomes appears to be necessary in some cases for
the generation of autolysosomes. In this report [17], the authors described that the proapoptotic
protein GZMB is selectively degraded upon autophagy activation in hypoxic cells thereby
inhibiting NK-mediated target cell apoptosis.
NK cell
Cytotoxic
granules
Tumor cell
Granzyme B / Perforin
Gigantosome
Granzyme B
degradation
Hypoxic stress
Autophagy 
activation
       
Autophagosome
Amphisome
Figure 2. Regulation of NK-mediated tumor cell lysis through selective degradation of NK-derived GZMB by autopha‐
gy in hypoxic tumor cells. Following the recognition of their targets NK cells secrete cytotoxic granules containing per‐
forin, granzyme B, and other hydrolytic enzymes to the target cells. These granules enter target cells and traffic to
enlarged endosomes called “gigantosomes.” Under hypoxia, excessive autophagy in target cells leads to the fusion of
autophagosomes with gigantosomes containing perforin and granzyme B and the formation of amphisomes. The selec‐
tive degradation of granzyme B by autophagy leads to hypoxic tumor cell escape from NK-mediated killing.
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In light of the in vitro observations, they investigated whether targeting autophagy enhances
in vivo NK-mediated antitumor immune response. BALB/c and C57BL/6 mice were trans‐
planted with syngeneic murine 4T1 breast adenocarcinoma and B16-F10 melanoma tumor
cells, respectively. They first demonstrated that NK cells control in vivo B16-F10 and 4T1 tumor
development as the depletion of host NK cells significantly increases tumor growth. There is
a significant decrease of autophagy-defective B16-F10 and 4T1 tumors volumes presumably
as a consequence of potentiation of tumor cell killing by NK cells. Overall, this study underlines
the inhibition of autophagy as a cutting-edge approach to overcome the suppressive effect of
the hypoxic tumor microenvironment on the antitumor immune response.
More recently, the role of autophagy in regulating the NK-mediated immune response was
extended to other tumor models. The clear cell renal cell carcinoma (ccRCC) is frequently
associated with tumor suppressor VHL gene mutations. Such mutations lead to the stabiliza‐
tion and accumulation of HIF-1α and HIF-2α and their target genes (Figure 3) Using VHL-
mutated-786-O renal carcinoma cells, it has been reported that the subsequent stabilization of
HIF-2α was strikingly associated with the resistance of 786-O cells to NK-mediated lysis.
Targeting HIF-2α or reconstitution of wild-type VHL in 786-O cells (hereafter referred to as
WT-7 cells) significantly decreased the level of HIF-2α and restored the resistance of 786-O
cells to NK-mediated lysis. These results highlight the critical role of HIF-2α in activating an
intrinsic mechanism that makes renal cell carcinoma (RCC) less sensitive to NK cell attack. To
gain further insight into the mechanism by which HIF-2α regulates RCC susceptibility to NK-
mediated lysis, global gene expression profiling was performed on control and siRNA-HIF-2α-
transfected 786-O cells. The result showed that the gene inositol 1,4,5-triphosphate receptor,
type I (ITPR1) was overexpressed in 786-O as compared to HIF-2α-defective cells. Interest‐
ingly, targeting ITPR1 in 786-O was sufficient to dramatically restore NK-mediated lysis of
these cells. These findings predict that the accumulation of HIF-2α in VHL-mutated 786-O cells
leads to the overexpression of ITPR1 which subsequently alters the susceptibility to NK cell
attack. Chromatin immunoprecipitation experiment further showed an HIF-2α enrichment of
the ITPR1 promoter fragment containing HRE-7 in 786-O compared to WT-7 cells indicating
that ITPR1 is a direct target of HIF-2α. Interestingly, immunochemistry analysis showed a
positive correlation between ITPR1 and HIF-2α expression in RCC patients. They next
analyzed whether the accumulation of ITPR1 in 786-O cells was associated with the induction
of autophagy. The authors were not able to detect any difference in the activation of autophagy
in VHL-mutated 786-O and VHL-corrected WT-7 cells cultured without NK effectors. How‐
ever, when co-cultured with NK cells, only VHL-mutated 786-O cells were able to activate
autophagy. These data strongly argue that the expression of ITPR1 is prerequisite for the
induction of autophagy in RCC by a signal derived from NK cells. This was further supported
by our data showing that targeting ITPR1 in 786-O cells abrogates the ability of NK cells to
activate autophagy [46, 47].
As discussed above, the activation of autophagy in target tumor cells impairs NK-mediated
tumor cell killing by degrading NK-derived GZMB. In accordance with this, higher level and
activity of NK-derived GZMB were detected in WT-7 as compared to 786-O cells exhibiting
increased level of autophagy. Targeting BECN1 in 786-O cells significantly restored GZMB
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level and activity. In light of our in vitro observations, the relevance of HIF-2α/ITPR1/autoph‐
agy pathway on NK-dependent antitumor immune response using Renca murine RCC was
investigated. The authors demonstrated first that NK cells control in vivo Renca tumor
development, by showing that the depletion of host NK cells significantly increased tumor
growth. Furthermore, they observed a significant decrease of tumor volume in mice engrafted
with ITPR1-defective Renca cells as compared to control cells. This decrease might be due to
the improvement of NK-mediated antitumor immune response. Consistent with this hypoth‐
esis, the regression of ITPR1 defective tumors was no longer observed in NK-depleted mice.
Taken together, these results suggest that inhibiting ITPR1/autophagy in tumors improves
their elimination by NK cells in vivo. While several studies claim that autophagy inhibitors
could improve anticancer therapies, other reports indicate that the use of autophagy inhibitors
may also have negative effect in the context of cancer immunotherapy. This study highlights
that targeting the autophagy sensor ITPR1 could be an alternative strategy to improve NK-
mediated antitumor immune response in renal carcinoma [46, 47].
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Figure 3. Targeting the autophagy sensor ITPR1 in renal cell carcinoma improves NK-mediated tumor cell killing. The
expression of mutated VHL in renal cell carcinoma leads to the accumulation of HIF-2α. Accumulated HIF-2α translo‐
cates to the nucleus and induces the transcription of its target gene ITPR1. ITPR1 plays a key role in sensing a yet un‐
defined signal derived from NK cells to activate autophagy by a mechanism that is not fully understood. The
activation of autophagy in renal carcinoma cells leads to the degradation of NK-derived granzyme B and ultimately
impairs NK-mediated tumor cell killing. At least 3 targets in this pathway (indicated in the figure as Targets 1, 2, and
3) may improve NK-mediated killing in renal cell carcinoma.
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3.3. Autophagy activation during epithelial-to-mesenchymal transition and tumor cell
plasticity
Epithelial-to-mesenchymal transition (EMT) has become one of the most exciting fields in
cancer biology. While its role in cancer cell invasion, metastasis and drug resistance is well
established [48, 49], the molecular basis of EMT-induced immune escape remains unknown.
EMT is a fundamental process in embryogenesis [50] that allows immobilized epithelial cells
to migrate as single cells to localize in different organs. Mechanisms driving EMT in develop‐
ment have also been co-opted by carcinoma cells to promote cell plasticity, invasion, and
metastasis [10]. Most carcinoma cells exhibit a spectrum of EMT phenotypes or “epithelial cell
plasticity,” which is directly linked to histological grading and thus contributes to prognosis,
stemness, immune suppression, and development of resistant cell variants [51–53]. Epithelial
cells are characterized by a well-defined apico-basal polarity involved in the establishment of
junctions between cells [54, 55]. The adhesive receptor E-cadherin is a critical component of
adherens junctions, and it is often downregulated during tumor progression. Adherens
junctions are thus most likely a major structure implicated in the control of epithelial cell
plasticity [56]. Upon exposure to EMT inducers, polarized normal or transformed epithelial
cells undergo morphological transition by launching a complex program of transcriptional,
translational and posttranslational mechanisms.
So far, the relationship between autophagy and EMT in tumors is not well elucidated and
studies addressing this issue in the context of tumor immune response are emerging. Thus,
the first evidence showing that the acquisition of an EMT phenotype in breast cancer cells is
associated with the induction of autophagy and the escape from T-cell-mediated lysis has been
published recently [57] (Figure 4). Indeed, using the breast MCF-7-derived tumor cells that
have undergone EMT following overexpression of wild-type SNAI1/SNAIL or the constitu‐
tively activated (SNAI1-6SA) protein, or by the acquisition of TNF/TNF-α resistance (2101
cells), the authors showed that EMT transcription factors are not the only way to induce an
enhanced phenotypic plasticity resulting in breast cancer cell resistance to CTLs. They also
showed that the acquisition of resistance to TNF leads to the induction of EMT and the
subsequent resistance to antigen-specific killer cells. It is worth noting that the acquisition of
resistance to TNF and the high EMT score of TNF-resistant (2101) cells suggest the existence
of a level of complexity in the EMT process in which multiple molecules act together to mediate
EMT, rather than the master regulators acting on their own.
Consistent with the role of autophagy as a cell protective mechanism, the authors further
investigated whether the activation of the EMT program in tumor cells is associated with the
induction of autophagy. The results showed that expression of SNAI1 in breast cancer cells
induces an epithelial dedifferentiation program that coincides with a drastic change in cell
morphology and the activation of autophagy flux. Interestingly, they found that BECN1 is
upregulated in mesenchymal cells compared to epithelial cells.
Although the molecular mechanism by which the EMT program affects the expression of
BECN1 remained to be addressed, several lines of evidence indicate that this may be related
to SNAI1- or EMT-dependent repression of miRNA(s) involved in modulation of BECN1
expression. Indeed, it has been reported that MIR30A inhibits the expression of BECN1, and
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that the transcription factors SNAI1 and ZEB1 bind to E-boxes in the MIR34A/B/C promoters,
thereby repressing MIR34A and MIR34B/C expression. While much remains to be learned
mechanistically, this result extended the role of SNAI1 as a regulator of autophagy and paved
the way to an interesting topic of research. Although targeting BECN1 in mesenchymal cells
is sufficient to restore CTL-mediated tumor cell lysis, it has no effect on cell morphology and
the expression of EMT markers. This finding suggests that autophagy is a downstream target
of the EMT program in breast cancer cells [57, 58]
4. Autophagy as a target for improving anticancer therapies
Intrinsic resistance mechanisms evolved by cancer cells are a key limitation to improve
response rates and survival of patients treated with anticancer therapies. It is now clearly
established that autophagy activation in cancer cells under stress conditions allows resistance
to chemotherapy [59], radiotherapy [60, 61], and immunotherapy [17, 44, 62, 63]. On the basis
of these observations, it is not surprising that autophagy has emerged as a potential therapeutic
target, and research efforts have intensified to develop autophagy inhibitors that could be used
in combination with anticancer therapies.
Pharmacological inhibitors of autophagy identified so far can be classified in two main groups
depending on which stage of the autophagy process is targeted. Sequestration inhibitors such
as 3-methyladenine (3-MA), LY294002, and wortmannin act at the early stage of the autophagy
pathway by inhibiting the class III phosphatidylinositol-3 kinase (PI3K). Recently, a potent
small molecule inhibitor of autophagy, called spautin-1, was identified which causes the
degradation of the class III PI3K complex by targeting BECN1 [64]. Most of other inhibitory
compounds act as later stage. Microtubule poisons such as vinca alkaloids, taxanes, nocoda‐
EMT
Tumor cell plasticity
Epithelial Tumor cells Mesenchymal Tumor 
cells
Autophagy induction
Autophagosomes
CTL
CTL
Mesenchymal markers
Epithelial markers
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Figure 4. The acquisition of an EMT phenotype of tumor cells through loss of epithelial and gain of mesenchymal
markers confers resistance to CTL-mediated lysis through autophagy induction.
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zole, and colchicine cause blockade of autophagosome and lysosome fusion. Inhibitors of
lysosomal enzymes (e.g., leupeptin, pepstatin A, and E-64d) or compounds that elevate
lysosomal pH (e.g., bafilomycin A1, chloroquine) impair autophagy through the inhibition of
cargo degradation by lysosomal hydrolases (reviewed in [28]). Chloroquine (CQ) and its
derivative hydroxychloroquine (HCQ) have long been used as antimalarial and antirheumatic
drug, and they were the only autophagy inhibitors approved by the US Food and Drug
Administration. As single agent, CQ has shown anticancer activity in lymphoma [65], pan‐
creatic [66], and breast cancers [67]. In addition, the use of CQ or HCQ in combination with
conventional therapies has provided convincing results in preclinical models [68]. Indeed,
autophagy blockade enhances anticancer effects of apoptosis-inducing agents [69] and Src
family kinase inhibitors [70]. Moreover, this strategy has shown promising results on patient’s
survival in the first phase III clinical trial using CQ as adjuvant treatment to conventional
anticancer therapy for glioblastoma [71]. Currently, more than 30 clinical trials are registered
with the National Cancer Institute to evaluate the effects of autophagy inhibition in a variety
of human cancers (http://clinicaltrials.gov). The Table 1 summarize the clinical trials involving
CQ or HCQ in combinational treatment of refractory malignancies.
Cancer type Drug intervention Phase status Clinical trial ID Title of the clinical trial
Pancreatic cancer HCQ
+Gemcitabine
+Abraxane
I/II
Active
NCT01506973 A Phase I/II/Pharmacodynamic Study
of Hydroxychloroquine in
Combination with Gemcitabine/
Abraxane to Inhibit Autophagy in
Pancreatic Cancer
Breast cancer HCQ II
Active
NCT01292408 Autophagy Inhibition Using
Hydrochloroquine in Breast Cancer
Patients
NSCL cancer HCQ
+Paclitaxel
+Carboplatin
+Bevacizumab
II
Active
NCT01649947 Modulation of Autophagy in Patients
with Advanced/Recurrent Non-small
Cell Lung Cancer - Phase II
Renal cancer HCQ+RAD001 I/II
Active
NCT01510119 Autophagy Inhibition to Augment
mTOR Inhibition: A Phase I/II Trial
of RAD001 and Hydroxychloroquine
in Patients with Previously Treated
Renal Cell Carcinoma
SCLC CQ
+Chemotherapy
+Radiotherapy
I
Active
NCT00969306 Chloroquine as an Anti-Autophagy
Drug in Stage IV Small Cell Lung
Cancer (SCLC) Patients
Colorectal cancer HCQ+FOLFOX
+Bevacizumab
I/II
Active
NCT01206530 FOLFOX/Bevacizumab/
Hydroxychloroquine (HCQ) in
Colorectal Cancer
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Cancer type Drug intervention Phase status Clinical trial ID Title of the clinical trial
Solid tumors HCQ+Sorafenib I
Active
NCT01634893 Oral Hydroxychloroquine Plus Oral
Sorafenib to Treat Patients with
Refractory or Relapsed Solid Tumors
Solid tumors CQ+Carboplatin
+Gemcitabine
I
Active
NCT02071537 Chloroquine in Combination with
Carboplatin/Gemcitabine in
Advanced Solid Tumors
Solid tumors HCQ
+Temsirolimus
I
Active
NCT00909831 Hydroxychloroquine and
Temsirolimus in Treating Patients
with Metastatic Solid Tumors that
Have not Responded to Treatment
Chronic myeloid
leukemia
HCQ
+Imatinib
mesylate
II
Active
NCT01227135 Imatinib Mesylate with or without
Hydroxychloroquine in Treating
Patients with Chronic Myeloid
Leukemia
Pancreatic cancer HCQ
+Gemcitabine
+Nab-Paclitaxel
II
Active
NCT01978184 Randomized Phase II Trial of Pre-
operative Gemcitabine and Nab
Paclitacel with or without
Hydroxychloroquine
Melanoma, prostate
or
kidney cancers
HCQ+MK2206 I
Active
NCT01480154 Akt Inhibitor MK2206 and
Hydroxychloroquine in Treating
Patients with Advanced Solid
Tumors, Melanoma, Prostate or
Kidney Cancer
Multiple myeloma HCQ
+Cyclophosphamide
+Dexamethasone
+Sirolimus
I
Active
NCT01689987 Hydroxychloroquine,
Cyclophosphamide, Dexamethasone,
and Sirolimus in Treating Patients
with Relapsed or Refractory Multiple
Myeloma
Solid tumors HCQ+Vorinostat I
Active
NCT01023737 Hydroxychloroquine + Vorinostat in
Advanced Solid Tumors
Pancreatic cancer HCQ
+Radiotherapy
II
Active
NCT01494155 Short Course Radiation Therapy with
Proton or Photon Beam Capecitabine
and Hydroxychloroquine for
Resectable Pancreatic Cancer
Glioma HCQ
+Radiotherapy
II
Active
NCT01602588 A Randomised Trial Investigating the
Additional Benefit of
Hydroxychloroquine (HCQ) to Short
Course Radiotherapy (SCRT) in
Patients Aged 70 Years and Older
with High Grade Gliomas (HGG)
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Cancer type Drug intervention Phase status Clinical trial ID Title of the clinical trial
Soft tissue sarcoma HCQ+Sirolimus II
Active
NCT01842594 A Phase II Trial of Combined
Hydroxychloroquine and Sirolimus
in Soft Tissue Sarcoma
Melanoma HCQ
+Vemurafenib
I
Active
NCT01897116 A Phase I Trial of Vemurafenib and
Hydroxychloroquine in Patients with
Advanced BRAF Mutant Melanoma
Renal cancer HCQ+Aldesleukin I/II
Active
NCT01550367 Study of Hydroxychloroquine and
Aldesleukin in Renal Cell Carcinoma
Patients (RCC)
Colorectal cancer HCQ+Vorinostat II Approved NCT02316340 Vorinostat Plus Hydroxychloroquine
Versus Regorafenib in Colorectal
Cancer
Advanced cancer HCQ+Vorinostat or
Sirolimus
I
Active
NCT01266057 Sirolimus or Vorinostat and
Hydroxychloroquine in Advanced
Cancer
Prostate cancer HCQ
+Navitoclax
+Abiraterone acetate
II
Active
NCT01828476 Navitoclax and Abiraterone Acetate
with or without Hydroxychloroquine
in Treating Patients with Progressive
Metastatic Castrate Refractory
Prostate Cancer
Melanoma HCQ
+Dabrafenib
+Trametinib
I/II
Active
NCT02257424 The BAMM Trial: BRAF, Autophagy
and MEK Inhibition in Metastatic
Melanoma: A Phase I/2 Trial of
Dabrafenib, Trametinib and
Hydroxychloroquine in Patients with
Advanced BRAF Mutant Melanoma
Solid tumors HCQ
+Temozolomide
I
Active
NCT00714181 Hydroxychloroquine and
Temozolomide in Treating Patients
with Metastatic or Unresectable Solid
Tumors
Multiple myeloma HCQ+Bortezomib I/II
Active
NCT00568880 Hydroxychloroquine and Bortezomib
in Treating Patients with Relapsed or
Refractory Multiple Myeloma
Pancreatic cancer HCQ
+Gemcitabine
I/II
Closed
NCT01128296 Study of Pre-surgery Gemcitabine +
Hydroxychloroquine (GcHc) in Stage
IIb or III Adenocarcinoma of the
Pancreas
Colorectal cancer HCQ
+Capecitabine
+Oxaliplatin
+Bevacizumab
II
Closed
Hydroxychloroquine, Capecitabine,
Oxaliplatin, and Bevacizumab in
Treating Patients with Metastatic
Colorectal Cancer
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Cancer type Drug intervention Phase status Clinical trial ID Title of the clinical trial
Solid tumors HCQ
+Sunitinib malate
I
Closed
NCT00813423 Sunitinib Malate and
Hydroxychloroquine in Treating
Patients with Advanced Solid
Tumors that Have not Responded to
Chemotherapy
Multiple myeloma Rapamycin or HCQ
+Cyclophosphamide
+Dexamethasone
NS
Closed
NCT01396200 Cyclophosphamide and Pulse
Dexamethasone with Rapamycin or
Hydroxychloroquine
Glioblastoma HCQ
+Radiotherapy
+Temozolomide
I/II
Closed
NCT00486603 Hydroxychloroquine, Radiation
Therapy, and Temozolomide in
Treating Patients with Newly
Diagnosed Glioblastoma Multiforme
Table 1. Examples of clinical trials involving autophagy inhibitors in combination with anticancer therapies (http://
cancer.gov/clinicaltrials). CQ: chloroquine; HCQ: hydroxychloroquine; NSCL: non-small cell lung; SCLC: small cell
lung cancer; NS: not specified.
Despite the encouraging preclinical results supporting the use of autophagy blockers in
combination with chemotherapy, more attention should be paid to evaluate the impact of such
inhibitors on tumor cell microenvironment. Indeed, recent evidence has emphasized that the
cross-talk between cancer cells, and their microenvironment is crucial in determining efficient
anticancer immune responses [72, 73]. It is now clear that a potent antitumor immune response
is an important prognostic factor for cancer patient overall survival [74], suggesting that
simultaneously blocking autophagy in tumor cells and boosting the immune system may be
of critical importance to achieve successful anticancer treatment. We recently demonstrated
that increased autophagy in tumor cell suppressed the antitumor immune response and that
autophagy blockade enhances CTL- and NK-mediated tumor cell killing once they have been
activated to lyse tumor cells [17, 63]. Given the limited successes encountered by many
immunotherapeutic approaches, these data imply that strategies based on adoptive transfer
of T cells, dendritic cell (DC) vaccines, or administration of antibodies or recombinant
cytokines such as IL-2, could only be effective if the blockade of autophagy is effective in tumor
cells [68]. Indeed, Liang et al. showed that the combination of high dose of Interleukin-2 (IL-2)
with CQ promotes long-term survival, decreased toxicity, and enhanced immune cell prolif‐
eration and infiltration in advanced murine metastatic liver tumor model [75]. This group has
now initiated a clinical protocol to evaluate the combinational administration of IL-2 and HCQ
in patients with advanced renal cell cancer.
While experimental and preclinical studies were mainly focused on the rational to use
autophagy inhibitors in cancer therapy, pharmacological approaches aiming to upregulate
autophagy have recently received considerable attention. Accumulating evidence highlights
that autophagy plays a crucial role in increasing the immunogenicity of tumor cell and actively
participates in tumor-associated antigen processing and presentation [76]. Indeed, cancer cell-
associated autophagy contributes to immunogenic cell death (ICD) through the release/
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exposure of immunostimulatory danger signals that stimulate the antitumor immune re‐
sponse. Such signaling molecules include secreted ATP, surface-exposed calreticulin, and high
mobility group box 1 (HMGB1) release [77, 78]. This important role of autophagy in eliciting
ICD was reported in a recent study showing how autophagy-competent cells, but not autoph‐
agy-deficient cells, enable to release ATP and recruit dendritic cells and T lymphocytes into
the tumor bed in mice [79]. Recently, the same group has confirmed that chemotherapy-
induced autophagy in cancer cells determines the outcome of melanoma therapy. Systemic
treatment with the anthracycline mitoxantrone reduced the growth of autophagy-competent
melanomas but not autophagy-deficient tumors. This growth-inhibitory activity of mitoxan‐
trone observed on autophagy-competent melanomas was shown to be mediated through CD4+
and CD8+ T lymphocytes, suggesting that autophagy is required to trigger a potent anticancer
response [80].
Furthermore, it has been described that autophagosomes are essential carriers for cross-
presentation of tumor-associated antigens [81]. Li et al. have demonstrated that the induction
of autophagy in tumor cells, following exposure to alpha-tocopheryloxyacetic acid (alpha-
TEA), generates double membrane-bound autophagosomes containing antigens that enhance
the cross-priming of CD8+ T lymphocytes. Moreover, the inhibition of autophagy, with 3-MA
or by specific silencing of Atg12, partially blocks T-cell activation. The authors showed that
vaccination with DC pulsed with autophagosome-enriched fraction, derived from tumor cells
treated in vitro with alpha-TEA, decreased lung metastasis and increased survival of tumor-
bearing mice [82]. Therefore, an autophagy inducer, such alpha-TEA, might be exploited as
adjuvant therapy to improve efficacy of immune modulator of T-cell response (anti-CTLA-4
antibody). Moreover, the same group also reported that vaccination with autophagosome-
enriched of defective ribosomal products (called DRibbles) or DRibbles loaded onto DC is a
potent inducer of the antitumor response in murine cancer models when associated with IFN-
γ and Toll-like receptor agonist [83]. Based on these findings, a clinical study was initiated to
investigate the efficacy of DRibbles vaccine in patients with non-small cell lung cancer.
Recently, Amaravadi et al. highlighted that cancer patients are suffering from a “systemic
autophagic syndrome,” meaning that autophagy is activated in tumor cells while suppressed
in immune effectors [68]. Taken together, these observations emphasize that future therapeutic
approaches may combine ex vivo autophagy induction in immune cells and systemic autoph‐
agy inhibition to improve efficacy of immunotherapies. As antigen processing and delivery to
major histocompatibility complex (MHC) Class I and II molecules into APC is mediated
through autophagy cargos, efficient DC vaccines may require their isolation from patients,
followed by ex vivo activation with tumor-associated antigens, and reintroduction of the
matured DC that would facilitate priming of CD8+ T cells.
5. Conclusion
The ability of cancer cells to evade immune surveillance and resist immunotherapy raises
fundamental questions about how tumor cells survive in the presence of a competent immune
system. To address this issue, studies have primarily focused on the mechanisms by which
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tumor cells avoid recognition by the immune system without considering the impact of the
tumor microenvironment. Thus, despite intense investigation, the relatively modest gains
provided by immunotherapy can be in part attributed to the activation of mechanisms
suppressing the antitumor immunity. It is now clearly established that the majority of these
mechanisms are likely evolved in the local tumor microenvironment. In line with this, it may
be more accurate to consider cancer, which was initially thought to be a disease of cells, then
of genes and then of genomes, as a disease of the microenvironment. While remarkable and
fairly rapid progresses have been made over the past two decades regarding the role of the
microenvironment in cancer biology and treatment, our understanding of its actual contribu‐
tion in tumor resistance to immune cell attack is still fragmented.
Emerging data indicate that, by inducing autophagy, hypoxia in the tumor microenvironment
plays key role in mediating tolerance to immune cell attack. Therefore, an understanding of
how autophagy plays such a role may allow better understanding of tumor adaptation and
evolution, and ultimately lead to improve the efficacy of therapies.
Despite recent advances in our understanding about the role of autophagy in cancer, the
emergence of consensual strategy implying autophagy modulators in anticancer therapy is
still challenging. Indeed, harnessing autophagy for therapeutic purposes will require careful
consideration on whether, when and how autophagy is induced as a prosurvival mechanism,
or is recruited to promote cancer cell killing. To date, most of the studies have focused on the
impact of autophagy on tumor cells themselves but it should be more accurate to consider
autophagy in the context of the tumor microenvironment. It has been increasingly clear that
autophagy may influence the cross-talk between cancer and immune cells, leading to either
immunoevasion or immunostimulation. Further knowledge on the impact of autophagy in
tumor cells as well as in the tumor microenvironment is necessary to tailor therapies that
selectively block suppressive mechanisms that impede antitumor response while promoting
the antitumor immunity.
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